Skip to main content

Advertisement

Table 1 Baseline characteristics of patients included in this post-hoc analysis of the Sharafkhaneh et al. study [16]

From: Reliever salbutamol use as a measure of exacerbation risk in chronic obstructive pulmonary disease

  BUD/FORM FORM Total
(n = 407) (n = 403) (n = 810)
Male, n (%) 262 (64.4) 229 (56.8) 491 (60.6)
Age, years (range) 63.8 (40–86) 62.5 (40–87) 63.2 (40–87)
Pre-BD FEV1, % predicted 33.0 (10.5) 32.4 (10.1) 32.7 (10.3)
Post-BD FEV1, % predicted 37.9 (11.8) 37.5 (12.4) 37.7 (12.1)
Pre-BD FEV1/FVC ratio, % 45.9 (11.3) 46.1 (11.1) 46.0 (11.2)
Smoking history
 Current smokers, n (%) 138 (33.9) 154 (38.2) 292 (36.0)
 Pack-years (range) 52.6 (10–200) 52.2 (10–258) 52.4 (10–258)
Most common COPD medications before run-in, n (%)
 β2-adrenergic agonists (SABA/LABA) 320 (78.6) 321 (79.7) 641 (79.1)
 Adrenergics/other drugs for obstructive airway diseases 198 (48.6) 196 (48.6) 394 (48.6)
 Long-acting muscarinic antagonist 123 (30.2) 109 (27.0) 232 (28.6)
 Inhaled corticosteroids 108 (26.5) 117 (29.0) 225 (27.8)
No. of exacerbations in the past 12 months, n (%)
 1 244 (60.0) 234 (58.1) 478 (59.0)
 2 95 (23.3) 99 (24.6) 194 (24.0)
 3 36 (8.8) 38 (9.4) 74 (9.1)
 4 22 (5.4) 19 (4.7) 41 (5.1)
  ≥ 5 10 (2.5) 13 (3.2) 23 (2.8)
Mean reliever use, inhalations/daya 5.8 (4.6) 6.0 (4.5) 5.9 (4.6)
Patients taking ICS at baseline, n % 108 (26.5) 117 (29.0) 225 (2.8)
  1. Data shown as mean (±SD), unless otherwise stated. Current smokers include habitual and occasional smokers
  2. BD bronchodilator, BUD budesonide, FEV 1 forced expiratory volume in 1 s, FORM formoterol, FVC forced vital capacity, ICS inhaled corticosteroid, LABA long-acting β2-agonists, SABA short-acting β2-agonists, SD standard deviation
  3. aBaseline: 2-week run-in period